How to appeal a CareFirst BCBS prostate cancer denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for prostate cancer

Cited policy: BCBS Lynparza (Olaparib) for HRR-mutated Metastatic Castration-Resistant Prostate Cancer

Adult mCRPC with deleterious or suspected-deleterious germline OR somatic HRR mutation (FDA-approved test). HRR panel per PROfound: BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L. Prior progression on enzalutamide OR abiraterone (monotherapy indication). For PROpel combo (olaparib+abiraterone+prednisone): BRCA-mutated 1L mCRPC. Castrate testosterone <50 ng/dL. Olaparib 300 mg PO BID.

How CareFirst BCBS denies prostate cancer — and how to counter it

Where CareFirst BCBS pushes back: 1) Only BRCA1/2 covered; 2) HRR result must be germline only; 3) Insufficient ARSI failure for monotherapy.

Counter-arguments that hold up: PROfound NEJM 2020 Hussain — olaparib HRR-mutated mCRPC post-ARSI rPFS HR 0.34 (Cohort A BRCA/ATM) + 0.49 (overall HRR). FDA May 19, 2020 monotherapy label covers 14-gene HRR panel, NOT BRCA-only. Both germline AND somatic HRR mutations qualify per FDA label and NCCN v1.2025. PROpel NEJM Evid 2022 + Lancet 2023 — olaparib+abiraterone 1L mCRPC rPFS benefit (FDA narrowed combo label May 2023 to BRCA-mutated). NCCN v1.2025 Category 1 for HRR-mutated mCRPC post-ARSI.

What CareFirst BCBS typically denies for prostate cancer

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For prostate cancer, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the prostate cancer treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Pluvicto (177Lu-PSMA-617)
• Xofigo (radium-223)
• Xtandi (enzalutamide)
• Erleada (apalutamide)
• Nubeqa (darolutamide)
• Zytiga (abiraterone)

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.